This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kulesz-Martin, M F Articles by Lee, L Search for Related Content PubMed PubMed Citation Articles by Kulesz-Martin, M F Articles by Lee, L

Endogenous p53 protein generated from wild-type alternatively spliced p53 RNA in mouse epidermal cells.

Department of Experimental Therapeutics, Roswell Park Cancer Institute, Buffalo, New York 14263.

ABSTRACT

We previously demonstrated that a wild-type alternatively spliced p53 (p53as) RNA exists in mouse cultured cells and normal mouse tissues at approximately 25 to 33% of the level of the major p53 RNA form. The alternative RNA transcript is 96 nucleotides longer than the major transcript as a result of alternative splicing of intron 10 sequences. The protein expected to be generated from the p53as transcript is 9 amino acids shorter than the major p53 protein and has 17 different amino acids at the carboxyl terminus. We report here that p53as protein exists in nontransformed and malignant epidermal cells and is localized to the nucleus. In addition, p53as protein is preferentially expressed during the G2 phase of the cell cycle and in cells with greater than G2 DNA content compared with the major p53 protein, which is preferentially expressed in G1. The p53as immunoreactivity is elevated and shifted to the G1 phase of the cell cycle following actinomycin D treatment of nontransformed cells but not malignant cells. In view of the dimerization and tetramerization of p53 protein which may be necessary for its DNA binding and transcriptional activation activities, the presence of p53as protein in cells has important implications for understanding the physiological function(s) of the p53 gene.

This article has been cited by other articles:

• Riley, K. J.-L., Maher, L. J. III (2007). p53 RNA interactions: New clues in an old mystery. RNA 13: 1825-1833 [Abstract] [Full Text]  
• Johnson, J., Lagowski, J., Sundberg, A., Lawson, S., Liu, Y., Kulesz-Martin, M. (2007). p73 Loss Triggers Conversion to Squamous Cell Carcinoma Reversible upon Reconstitution with TAp73{alpha}. Cancer Res. 67: 7723-7730 [Abstract] [Full Text]  
• Mills, A. A. (2005). p53: link to the past, bridge to the future. Genes Dev. 19: 2091-2099 [Full Text]  
• Wright, J. W., Stouffer, R. L., Rodland, K. D. (2005). High-Dose Estrogen and Clinical Selective Estrogen Receptor Modulators Induce Growth Arrest, p21, and p53 in Primate Ovarian Surface Epithelial Cells. J. Clin. Endocrinol. Metab. 90: 3688-3695 [Abstract] [Full Text]  
• Harms, K. L., Chen, X. (2005). The C Terminus of p53 Family Proteins Is a Cell Fate Determinant. Mol. Cell. Biol. 25: 2014-2030 [Abstract] [Full Text]  
• Knights, C. D., Liu, Y., Appella, E., Kulesz-Martin, M. (2003). Defective p53 Post-translational Modification Required for Wild Type p53 Inactivation in Malignant Epithelial Cells with mdm2 Gene Amplification. J. Biol. Chem. 278: 52890-52900 [Abstract] [Full Text]  
• Cassiday, L. A., Maher III, L. J. (2002). Having it both ways: transcription factors that bind DNA and RNA. Nucleic Acids Res 30: 4118-4126 [Abstract] [Full Text]  
• Almog, N., Milyavsky, M., Stambolsky, P., Falcovitz, A., Goldfinger, N., Rotter, V. (2001). The role of the C' terminus of murine p53 in the p53/mdm-2 regulatory loop. Carcinogenesis 22: 779-785 [Abstract] [Full Text]  
• Laverdiere, M., Beaudoin, J., Lavigueur, A. (2000). Species-specific regulation of alternative splicing in the C-terminal region of the p53 tumor suppressor gene. Nucleic Acids Res 28: 1489-1497 [Abstract] [Full Text]  
• Janus, F., Albrechtsen, N., Knippschild, U., Wiesmuller, L., Grosse, F., Deppert, W. (1999). Different Regulation of the p53 Core Domain Activities 3'-to-5' Exonuclease and Sequence-Specific DNA Binding. Mol. Cell. Biol. 19: 2155-2168 [Abstract] [Full Text]  
• Zhou, X., Wang, X. W., Xu, L., Hagiwara, K., Nagashima, M., Wolkowicz, R., Zurer, I., Rotter, V., Harris, C. C. (1999). COOH-Terminal Domain of p53 Modulates p53-mediated Transcriptional Transactivation, Cell Growth, and Apoptosis. Cancer Res. 59: 843-848 [Abstract] [Full Text]  
• Tron, V. A., Trotter, M. J., Tang, L., Krajewska, M., Reed, J. C., Ho, V. C., Li, G. (1998). p53-Regulated Apoptosis Is Differentiation Dependent in Ultraviolet B-Irradiated Mouse Keratinocytes. Am. J. Pathol. 153: 579-585 [Abstract] [Full Text]  
• Bian, J., Sun, Y. (1997). p53CP, a putative p53 competing protein that specifically binds to the consensus p53 DNA binding sites: A third member of the p53 family?. Proc. Natl. Acad. Sci. USA 94: 14753-14758 [Abstract] [Full Text]  
• Wu, Y., Huang, H., Miner, Z., Kulesz-Martin, M. (1997). Activities and response to DNA damage of latent and active sequence-specific DNA binding forms of mouse p53. Proc. Natl. Acad. Sci. USA 94: 8982-8987 [Abstract] [Full Text]  
• Ko, L J, Prives, C (1996). p53: puzzle and paradigm.. Genes Dev. 10: 1054-1072  
• Hupp, T. R., Lane, D. P. (1995). Two Distinct Signaling Pathways Activate the Latent DNA Binding Function of p53 in a Casein Kinase II-independent Manner. J. Biol. Chem. 270: 18165-18174 [Abstract] [Full Text]